Li Wei, Wang Weili, Liao Ping, Song Kun, Zhu Zhanwei, Wang Kuansong, Liu Zhaoqian, Zhang Wei, Xie Shangchen, He Yijing, Mcleod Howard L, Chen Ling
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, 110 Xiangya Road, Changsha, Hunan, 410078, PR China.
Department of Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha, Hunan, 410078, PR China.
Pharmacogenomics. 2020 Jul;21(11):751-759. doi: 10.2217/pgs-2019-0102. Epub 2020 Jul 3.
Tumor-infiltrating lymphocytes (TILs) and postoperative chemotherapeutics interact in the tumor micro-environment. This interaction has not been well investigated in gastric cancer. A total of 129 patients were divided into high or low TILs based on the median number of positive CD3 and FoxP3 T cells, which was assessed by immunocytochemistry. Cox regression analysis showed that the stage III disease with shorter overall survival was significant. The analysis showed that high numbers of CD3 or FoxP3 T cells have better clinical outcomes in FOLFOX-treated patients. High CD3 and FoxP3 T-cell infiltration was associated with better clinical outcomes in patients with gastric cancer treated with FOLFOX, suggesting TILs incorporated into algorithms to improve the therapeutic efficacy of optimal chemotherapy.
肿瘤浸润淋巴细胞（TILs）与术后化疗药物在肿瘤微环境中相互作用。这种相互作用在胃癌中尚未得到充分研究。根据免疫细胞化学评估的CD3和FoxP3阳性T细胞的中位数，将129例患者分为TILs高或低两组。Cox回归分析表明，III期疾病且总生存期较短具有显著性。分析表明，在接受FOLFOX治疗的患者中，大量的CD3或FoxP3 T细胞具有更好的临床结局。CD3和FoxP3 T细胞的高浸润与接受FOLFOX治疗的胃癌患者更好的临床结局相关，提示TILs可纳入算法以提高最佳化疗的治疗效果。
